{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:27Z","timestamp":1792788567854,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Talanta"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.talanta.2020.121641","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T11:29:26Z","timestamp":1600255766000},"page":"121641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Simultaneous determination of 8 beta-lactams and linezolid by an ultra-performance liquid chromatography method with UV detection and cross-validation with a commercial immunoassay for the quantification of linezolid"],"prefix":"10.1016","volume":"221","author":[{"given":"D.","family":"Fage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Deprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.talanta.2020.121641_bib1","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.talanta.2020.121641_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","article-title":"Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections?","volume":"78","author":"Muller","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.talanta.2020.121641_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.diagmicrobio.2014.04.007","article-title":"How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?","volume":"79","author":"Felton","year":"2014","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.talanta.2020.121641_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient \u2014 concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.talanta.2020.121641_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568005014606099","article-title":"The discovery of linezolid, the first oxazolidinone antibacterial agent","volume":"1","author":"Ford","year":"2001","journal-title":"Curr. Drug Targets - Infect. Disord."},{"key":"10.1016\/j.talanta.2020.121641_bib6","series-title":"WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update","year":"2016"},{"key":"10.1016\/j.talanta.2020.121641_bib7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijantimicag.2011.05.007","article-title":"Clinical pharmacokinetic\/pharmacodynamic profile of linezolid in severely ill Intensive Care Unit patients","volume":"38","author":"Dong","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2020.121641_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.05.009","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients","volume":"48","author":"Dong","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2020.121641_bib9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ijantimicag.2018.01.021","article-title":"Population pharmacokinetics\/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy","volume":"51","author":"Ide","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2020.121641_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.talanta.2020.121641_bib11","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijantimicag.2017.01.017","article-title":"Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis","volume":"49","author":"Kamp","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2020.121641_bib12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/INF.0b013e3182154b05","article-title":"Meropenem\/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis, Pediatr","volume":"30","author":"Dauby","year":"2011","journal-title":"Inf. Disp. J."},{"key":"10.1016\/j.talanta.2020.121641_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5588\/ijtld.11.0414","article-title":"Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis","volume":"16","author":"Payen","year":"2012","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.talanta.2020.121641_bib14","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/09031936.00124312","article-title":"Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB","volume":"41","author":"De Lorenzo","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.talanta.2020.121641_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.talanta.2020.121641_bib16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2020.121641_bib17","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","article-title":"Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections","volume":"41","author":"Cattaneo","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2020.121641_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","article-title":"Therapeutic drug management of linezolid: a missed opportunity for clinicians?","volume":"48","author":"Cattaneo","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.talanta.2020.121641_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jpba.2013.11.004","article-title":"Simultaneous analysis of antibiotics in biological samples by ultra high performance liquid chromatography\u2013tandem mass spectrometry","volume":"89","author":"Cazorla-Reyes","year":"2014","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2020.121641_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpba.2019.02.037","article-title":"LC-MS\/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples","volume":"169","author":"Ferrari","year":"2019","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2020.121641_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1179\/1973947814Y.0000000209","article-title":"Quantification of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in human plasma by liquid chromatography\/tandem mass spectrometry","volume":"27","author":"Barco","year":"2015","journal-title":"J. Chemother."},{"key":"10.1016\/j.talanta.2020.121641_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2014.08.026","article-title":"Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography\u2013electrospray ionization\u2013tandem mass spectrometry","volume":"102","author":"Kima","year":"2015","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2020.121641_bib23","first-page":"781","article-title":"Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC MS\/MS method with semi-automated sample preparation","volume":"53","author":"Zandera","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.talanta.2020.121641_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpba.2015.10.008","article-title":"Simultaneous determination of ceftaroline, daptomycin, linezolid and rifampicin concentrations in human plasma by on-line solid phase extraction coupled to high-performance liquid chromatography\u2013tandem mass spectrometry","volume":"118","author":"Gr\u00e9goire","year":"2016","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2020.121641_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1179\/1973947814Y.0000000209","article-title":"Quantification of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in human plasma by liquid chromatography\/tandem mass spectrometry","volume":"27","author":"Barco","year":"2015","journal-title":"J. Chemother."},{"key":"10.1016\/j.talanta.2020.121641_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jpba.2019.02.037","article-title":"LC-MS\/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples","volume":"169","author":"Ferrari","year":"2019","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2020.121641_bib27","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/jac\/dkt523","article-title":"An international, multicentre survey of beta-lactam antibiotictherapeutic drug monitoring practice in intensive care units","volume":"69","author":"Wong","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.talanta.2020.121641_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.talanta.2012.10.024","article-title":"Rapid quantification of six b-lactams to optimize dosage regimens in severely septic patients","volume":"103","author":"Wolff","year":"2013","journal-title":"Talanta"},{"key":"10.1016\/j.talanta.2020.121641_bib29","series-title":"Interference Testing in Clinical Chemistry","year":"1986"},{"key":"10.1016\/j.talanta.2020.121641_bib30","first-page":"579","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal - Part I","volume":"36","author":"Hubert","year":"2004","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2020.121641_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpba.2007.06.013","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal - Part II","volume":"45","author":"Hubert","year":"2007","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2020.121641_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jpba.2007.06.032","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal - Part III","volume":"45","author":"Hubert","year":"2007","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2020.121641_bib33","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jpba.2008.07.018","article-title":"Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal - Part IV. Examples of application","volume":"48","author":"Hubert","year":"2008","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2020.121641_bib34","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1007\/s11095-007-9291-7","article-title":"Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays","volume":"24","author":"Viswanathan","year":"2007","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.talanta.2020.121641_bib35","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1515\/cclm-2014-0833","article-title":"Exploration of the pre-analytical stability of \u03b2 -lactam antibiotics in plasma and blood \u2013 implications for therapeutic drug monitoring and pharmacokinetic studies","volume":"53","author":"Carlier","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.talanta.2020.121641_bib36","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpba.2017.05.037","article-title":"Therapeutic drug monitoring of beta-lactam antibiotics \u2013 influence of sample stability on the analysis of piperacillin, meropenem, ceftazidime and flucloxacillin by HPLC-UV","volume":"143","author":"Pinder","year":"2017","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.talanta.2020.121641_bib37","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1128\/AAC.00533-11","article-title":"Simultaneous determination of 12 \u03b2-lactam antibiotics in human plasma by high-performance liquid chromatography with UV detection: application to therapeutic drug monitoring","volume":"55","author":"Verdier","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.talanta.2020.121641_bib38","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1128\/AAC.00176-16","article-title":"Simultaneous determination of eight -lactam antibiotics, amoxicillin, cefazolin, cefepime, cefotaxime, ceftazidime, cloxacillin, oxacillin, and piperacillin, in human plasma by using ultra-high-performance liquid chromatography with ultraviolet detection","volume":"60","author":"Legrand","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.talanta.2020.121641_bib39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/FTD.0000000000000473","article-title":"Comparison of the ARK immunoassay with high-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of linezolid","volume":"40","author":"Castoldi","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.talanta.2020.121641_bib40","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.talanta.2020.121641_bib41","doi-asserted-by":"crossref","first-page":"iv7","DOI":"10.1093\/jac\/dkr072","article-title":"Linezolid pharmacokinetics and pharmacodynamics in clinical treatment","volume":"66","author":"Dryden","year":"2011","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Talanta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914020309322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039914020309322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T12:53:46Z","timestamp":1758545626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039914020309322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":41,"alternative-id":["S0039914020309322"],"URL":"https:\/\/doi.org\/10.1016\/j.talanta.2020.121641","relation":{},"ISSN":["0039-9140"],"issn-type":[{"value":"0039-9140","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of 8 beta-lactams and linezolid by an ultra-performance liquid chromatography method with UV detection and cross-validation with a commercial immunoassay for the quantification of linezolid","name":"articletitle","label":"Article Title"},{"value":"Talanta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.talanta.2020.121641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121641"}}